On-site pathology tests for infectious diseases in rural and remote locations can be just as reliable and accurate as tests carried out in a hospital laboratory, a new report from Flinders University shows.
On-site pathology tests for infectious diseases in rural and remote locations can be just as reliable and accurate as tests carried out in a hospital laboratory, a new report from Flinders University shows.
Flinders University researchers tested the quality of on-site pathology testing, or Point-of-Care-Testing (POCT), for molecular-based, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in over 100 remote Aboriginal and Torres Strait Islander communities across Australia.
“Our study demonstrates that when point-of-care testing models are effectively established and managed, the quality of pathology results can be equivalent to laboratory tests, and the benefits for patients are overwhelmingly evident,” says Dr Susan Matthews from the International Centre for Point-of-Care Testing at Flinders University.
“In Australia, POC testing supports hard-to-reach patients, including Indigenous communities in rural and remote areas, where long distances and social and cultural factors can prevent individuals from getting tested, meaning that infectious diseases can often be left untreated.
“The high prevalence among the Aboriginal and Torres Strait Islander population of infectious diseases like COVID-19, has consolidated demand for point-of-care diagnostic solutions particularly due to their cost-effectiveness, accessibility and ability to deliver immediate results,” she says.
The report assessed analytical quality in the Aboriginal and Torres Strait Islander COVID-19 Point-of-Care (POC) Testing Program in Australia which was launched in April 2020 to improve access to rapid molecular-based SARS-CoV-2 detection in remote communities.
“The program reached 105 communities across Australia and was found to have contributed to averting a significant number of COVID-19 infections, resulting in substantial cost savings to the healthcare system,” says Dr Matthews.
The analytical quality of the COVID-19 testing was supported by a robust operator training program and the implementation of a customised External Quality Assessment (EQA) program, the latter developed in partnership with the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP).
“The EQA program allowed us to assess the accuracy and reliability of the COVID-19 test results and confirmed the technical competency of the trained remote health service POCT operators.
“Our findings highlight an ongoing need for well-designed, cost effective and externally accredited EQA programs, not just for SARS-CoV-2 but also for other diseases that require POC testing.
“The COVID-19 program has now been expanded to include testing for Influenza A and B, and respiratory syncytial virus (RSV), as well as SARS-CoV-2 and has the potential to stem acute and infectious diseases in rural and remote areas whilst saving the government billions of dollars in health costs,” she adds.
POCT was first introduced to remote health centres in 1999 through the Quality Assurance for Aboriginal and Torres Strait Islander Medical Services (QAAMS) Program, which the Flinders University International Centre for Point-of-Care Testing continues to manage on behalf of the Australian Government.
The paper, External Quality Assessment (EQA) for SARS-CoV-2 RNA Point-of-Care Testing in Primary Healthcare Services: Analytical Performance over Seven EQA Cycles by Susan J. Matthews, Kelcie Miller, Kelly Andrewartha, Melisa Milic, Deane Byers, Peter Santosa, Alexa Kaufer, Kirsty Smith, Louise M. Causer, Belinda Hengel, Ineka Gow, Tanya Applegate, William D. Rawlinson, Rebecca Guy and Mark Shephard, was published this week in Diagnostics, DOI: 10.3390/diagnostics14111106
Journal
Diagnostics
Method of Research
Data/statistical analysis
Subject of Research
Human tissue samples
Article Title
External Quality Assessment (EQA) for SARS-CoV-2 RNA Point-of-Care Testing in Primary Healthcare Services: Analytical Performance over Seven EQA Cycles
Article Publication Date
26-May-2024
COI Statement
Investigators (R.G., M.S., K.A., S.J.M., W.D.R., T.A., K.S., B.H., L.M.C.) receive in-kind cartridges from Cepheid for a Medical Research Future Fund (MRFF)—Rapid Applied Research Translation (RART) grant; Scaling up infectious disease point-of-care testing for Indigenous people. R.G. and T.A. receive funding and in-kind contributions from Cepheid for an Australian Research Council (ARC) grant—Industrial Transformation Research Program (ITRP) Research Hub to Combat Antimicrobial Resistance. Customised SARS-CoV-2 External Quality Assessment (EQA) materials were manufactured by the RCPAQAP under a specification agreement and collaboration between the RCPAQAP, the Kirby Institute (UNSW) and Flinders University ICPOCT
Discover more from Science
Subscribe to get the latest posts sent to your email.